MT10109L in the Treatment of Glabellar Lines With or Without Concurrent Treatment of Lateral Canthal Lines



Status:Recruiting
Healthy:No
Age Range:18 - Any
Updated:3/23/2019
Start Date:October 26, 2018
End Date:January 1, 2021
Contact:Clinical Trials Registry Team
Email:IR‐CTRegistration@Allergan.com
Phone:877‐277‐8566

Use our guide to learn which trials are right for you!

A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of MT10109L (NivobotulinumtoxinA) for the Treatment of Glabellar Lines With or Without Concurrent Treatment of Lateral Canthal Lines

To evaluate the safety and efficacy of MT10109L for the treatment of glabellar lines (GL)
with or without concurrent treatment of lateral canthal lines (LCL) in participants with
moderate to severe GL and LCL.


Inclusion Criteria

• Female participants must not be pregnant or planning to get pregnant and willing to
minimize the risk of inducing pregnancy for the duration of the clinical study and
follow-up period.

Exclusion Criteria

- Known immunization or hypersensitivity to any botulinum toxin serotype.

- Any medical condition that may put the participant at increased risk with exposure to
MT10109L including diagnosed myasthenia gravis, Eaton-Lambert syndrome, amyotrophic
lateral sclerosis, or any other condition that might interfere with neuromuscular
function.

- History of facial nerve palsy.

- Any uncontrolled systemic disease.

- Anticipated need for treatment with botulinum toxin of any serotype for any reason
during the study (other than study intervention).

- Anticipated need for surgery or overnight hospitalization during the study.

- Prior exposure to botulinum toxin of any serotype for any reason.

- Prior periorbital surgery, facial lift (full face or mid-face), thread lift, brow
lift, or related procedures (eg, eyelid [blepharoplasty] and/or eyebrow surgery).

- Prior facial treatment with permanent soft tissue fillers, synthetic implantation (eg,
Gore-Tex®), and/or autologous fat transplantation.

- Current enrollment in an investigational drug or device study or participation in such
a study within 30 days of entry into this study.

- Females who are pregnant, nursing, or planning a pregnancy during the study.

- Participants who plan for an extended absence away from the immediate area of the
study site that would preclude them from returning for all protocol-specified study
visits.
We found this trial at
9
sites
Bellaire, Texas 77401
?
mi
from
Bellaire, TX
Click here to add this to my saved trials
Arlington, Virginia 22209
?
mi
from
Arlington, VA
Click here to add this to my saved trials
Coral Gables, Florida 33146
?
mi
from
Coral Gables, FL
Click here to add this to my saved trials
Glendale, Arizona 85308
?
mi
from
Glendale, AZ
Click here to add this to my saved trials
Hunt Valley, Maryland 21030
?
mi
from
Hunt Valley, MD
Click here to add this to my saved trials
Metairie, Louisiana 70006
?
mi
from
Metairie, LA
Click here to add this to my saved trials
?
mi
from
New York, NY
Click here to add this to my saved trials
Newport Beach, California
?
mi
from
Newport Beach, CA
Click here to add this to my saved trials
Vancouver, British Columbia
?
mi
from
Vancouver,
Click here to add this to my saved trials